SAT-341 Pharmacology and Metabolism of GLL398 an Oral Selective Estrogen Receptor Degrader for Endocrine Therapy of Breast Cancer

Selective estrogen receptor degrader (SERD) has proven clinically effective in treating advanced or metastatic breast cancer since the approval of fulvestrant by FDA in 2002. Recent expansion of indications as a first line monotherapy and as combination therapy with CDK4/6 inhibitors further demonst...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Shanchun, Hossain, Ahamed, Zhang, Changde, Mottamal, Madhu, Liu, Jiawang, Wiese, Thomas, Wang, Guangdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Tumor Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552000/
http://dx.doi.org/10.1210/js.2019-SAT-341

Ejemplares similares

Ejemplares similares